Novel Biomarkers

Pathway Diagnostics is developing the next generation of clinically relevant biomarkers that meet unaddressed medical needs in the areas of cardiovascular diseases, oncology, inflammatory and autoimmune diseases, infectious diseases and psychiatric disorders. We source novel biomarker opportunities from a variety of entities. Once in-licensed, due diligence and laboratory resources are utilized to effectively develop a clinical diagnostic assay, which may be deployed in clinical trials as well as commercialized via one of several market channels. Our current assay portfolio includes both protein as well as nucleic acid biomarkers.